Tendon healing has three phases: inflammatory, proliferative, and remodeling. BPC-157 works best during proliferation for its vascular effects, while IGF-1 boosters help remodeling but shouldn't run long because sustained elevation can activate cancer pathways. Timing compounds to the right phase matters; otherwise you're just adding noise.
The third rule for this is that timing is the protocol. Okay. Compounds without phase match timing are really just noise. You need to match the protocol to the biology. Now, if you think about this from the tendon aspect, you go through inflammatory, proliferative, and remodeling phases. Inflammatory phase is the first 0 to 7 days where you get all the cytokines and activity that's going to take place. You have then proliferation where there is vascular formation, etc. This may be a phase in particular, for instance, where BPC-157 has some value. And then later you go into the remodeling phase. Now, if you understand these phases, you would understand that remodeling isn't necessarily a place for BP-157 because that is stimulating more vascular proliferation, whereas you want to lay the foundations early for inflammation, proliferation, and then remodeling by using a growth hormone compound that perhaps increases IGF-1 levels and continue throughout. This is a limited phase. So in my mind, it does not make sense to use these compounds just continuously throughout. You want to use them in a critical window where you can impact your potential for healing, but you don't want to use them indefinitely. Also, which goes along with that, is that there may be some risk to having elevated IGF-1 levels for a long period of time, such as by using growth hormone compounds, because those can potentially fall into the same pathways that get down cancer pathways. And that's something to definitely be avoided, which I also think gets into screening, which I will talk about later.
